The Claim
Patients with coronary artery disease who achieve LDL cholesterol levels below 55 mg/dL are more frequently prescribed high-intensity statin therapy, independent of their lipid plaque density index.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In patients with coronary artery disease, those with LDL cholesterol below 55 mg/dL are more often prescribed high-intensity statins, regardless of the amount of plaque in their arteries.
See the scientific wording
Patients with coronary artery disease who achieve LDL cholesterol below 55 mg/dL are more likely to be on high-intensity statin therapy, regardless of their lipid plaque density index, indicating that LDL-C targets are influenced by treatment intensity rather than plaque phenotype alone.
Strong cholesterol-lowering drugs reduce the amount of bad cholesterol in the blood. This causes fat inside artery plaques to shrink as immune cells remove it. The plaques become tougher and less likely to break open, which prevents heart attacks and strokes.
What the research says
1 studyPeople with heart disease who get their bad cholesterol below 55 mg/dL are more likely to be on stronger statin pills — not because their plaques are different, but because doctors gave them stronger medicine. The type of plaque doesn’t decide the cholesterol level; the drug dose does.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.